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ABSTRACT 
Jennifer Ann Rutan: Regulation of autoreactive B cells during innate immune responses 
(Under the direction of Dr. Barbara J. Vilen) 
 
 A diverse repertoire of B cell specificities is critical to combat pathogenic threats, 
but this diversity is tinged with the threat of autoimmunity.   Autoimmune diseases such 
as systemic lupus erythematosus (SLE) underscore the need for strict regulation of B cell 
activation during immune responses.   Regulation of the adaptive immune response is 
dependent on B cell receptor (BCR) ligation, affinity of the BCR-antigen interaction, and 
the presence of costimulatory molecules.  Mechanisms of central tolerance and peripheral 
tolerance eradicate B cells that inappropriately bind self-antigens.  Autoreactive B cells 
that escape these mechanisms of tolerance and encounter antigen in the absence of 
costimulatory signals enter an unresponsive state known as anergy.  Anergic B cells do 
not differentiate into plasma cells, activate transcription factors such as Blimp-1 and 
XBP-1, or secrete immunoglobulin (Ig).  B cells can also be activated by toll-like 
receptor (TLR) ligands and contribute to the innate immune response, the first line of 
defense against pathogens.  Bacterial and viral components are the archetypical TLR 
ligands, but endogenous DNA and RNA can also bind TLRs and activate the innate 
immune system.   Therefore, it is critical to regulate the innate immune response to 
prevent autoimmunity, and this regulation requires unique mechanisms that are not 
necessarily dependent on BCR ligation.  Ideally, these mechanisms would also  
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discriminate between naïve and chronically antigen-experienced B cells, allowing naïve 
B cells to respond to threats while potentially autoreactive B cells remain quiescent.  We 
have recently described a mechanism where antigen-experienced B cells are regulated by 
IL-6 and sCD40L released by dendritic cells (DCs) and macrophages (MΦs) during 
innate immune responses.  Naïve B cells are unaffected by these factors, permitting a 
robust immune response in the absence of autoimmunity.  IL-6/sCD40L-mediated 
repression is dependent on ERK activation and “repressed” antigen-experienced cells 
exhibit a decrease in activated ERK in the nucleus.  Identifying new targets for SLE 
therapies could enable specific regulation of antigen-experienced B cells instead of non-
specific B cell depletion and immunosuppression.    
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1.1  Learning tolerance: a B cell’s story 
A diverse B cell repertoire is critical in combating pathogens, but inherent in 
generating diversity is the threat of autoimmunity.  In the bone marrow, central tolerance 
mechanisms such as deletion or receptor editing remove high affinity autoreactive B cells 
before they exit to the periphery (1-10).  Those that escape are subject to receptor 
revision (8, 11-14), peripheral deletion (15, 16), or a shortened lifespan because they fail 
to enter B cell follicles (17-22).  In rare cases, autoreactive B cells are fully functional but 
indifferent to their specific antigen (23-25).  Finally, many low affinity autoreactive B 
cells are maintained in an unresponsive state known as anergy.  Anergic B cells do not 
receive sufficient activation signals to differentiate into plasma cells or secrete 
immunoglobulin (Ig) in response to antigenic or mitogenic stimulation (26-29).  Their 
proliferative responses to B cell receptor (BCR) or toll-like receptor (TLR) signaling as 
well as their lifespans vary in different models (18, 30-35).  Some anergic B cells 
transduce BCR-derived signals (30, 32, 36-40), while others exhibit desensitized BCRs 
(30, 33, 41).  Quiescence is dependent on chronic exposure to self-antigen and occupancy 
of the BCR (42, 43).  Furthermore, ERK activation is critical in sustaining anergy during 
polyclonal stimulation by TLR ligands (27, 28).  Recently, it was demonstrated that 
anergy can be mediated by DCs and MΦs.  In the presence of TLR ligands, DCs and 
MΦs release IL-6 and sCD40L that selectively represses Ig secretion from autoreactive B 
cells (44, 45).  In the absence of DCs/MΦs and their soluble factors, autoreactive B cells 
regain the ability to secrete Ig, indicating that this mechanism of tolerance is reversible.  
These data suggest that autoreactive B cells must be maintained in close proximity to 
DCs/MΦs during innate immune responses to prevent autoimmunity.   
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The affinity and avidity of the antigen-BCR interaction determines whether 
developing B cells will be deleted, edited, anergized, or ignored (46).  Self-reactive B 
cells that survive these developmental checkpoints tend to bind self-antigens with low 
affinity and they remain anergic in the absence of costimulation by cognate T cells.  
Many of the early transgenic (Tg) models expressed BCRs with high affinities.  
However, concerns were raised that these models may not adequately reflect how bona 
fide low affinity self-antigens are regulated (1, 26).  To study the tolerance mechanisms 
regulating low-affinity B cells, new Ig Tg models were generated that expressed BCRs 
specific for double-stranded (ds) DNA, single-stranded (ss) DNA, rheumatoid factor 
(RF), insulin, and Smith antigen (Sm).  
 
1.2  A short history of Sm 
Sm antigens are conserved proteins that are indispensable in RNA splicing.  In 
1966, Sm was identified as a unique autoantigen, the first non-histone target of 
autoantibodies in systemic lupus erythematosus (SLE) patients (47).  Named for 15-year-
old Stephanie Smith, antibodies to Sm became one of the diagnostic criteria for SLE (48), 
detectable in 5-30% of SLE patients (48, 49).  Later studies correlated anti-Sm titers with 
kidney disease (50-53).  
The autoantibodies isolated from patient sera proved invaluable in the initial 
studies of the Sm proteins (54).  The small nuclear RNA (snRNA U1, U2, U4, or U5) in 
each small nuclear ribonucleic particle (snRNP) is predicted to thread through the center 
of a heptameric ring of Sm proteins (E, F, G, D1, D2, D3, and B/B') (55).  Three of the 
Sm proteins (D1, B, and D3) have long, positively charged tails that contact the pre-
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mRNA in the 5’ splice site region (56).  This interaction stabilizes the commitment 
complex formed when U1 snRNP binds the pre-mRNA substrate (57).  The remaining 
snRNPs, U2 and U4/U5/U6 (the triple snRNP) bind to pre-mRNA, rearrange to form the 
splicesome, and remove introns from the transcript (58).   
Self-antigens composed of protein and DNA or RNA can co-ligate the BCR with 
TLRs, potentially overcoming tolerance mechanisms and activating autoreactive B cells.  
For example, concomitant ligation of the BCR and TLR9 by chromatin:IgG immune 
complexes activates RF-specific B cells in the absence of T cell help or overt TLR 
stimulation (38, 59, 60).  Signaling through both the BCR and TLR9 is necessary to 
activate NF-κB in these B cells (37).  Recently, RNA-IgG immune complexes were 
shown to activate RF-specific B cells via TLR7 (39).  TLR7 binds ssRNA, a viral antigen 
that acts as a sensor of infection as well as a component of the U1 snRNP splicing 
complex, a known autoantigen in SLE (61, 62).  Aberrantly high expression of TLR7, or 
an increased burden of immune complexes and/or apoptotic cells, aggravates disease in 
lupus-prone mice.  For instance, the gene duplication of TLR7 in Yaa mice results in 
hyperactive B cells, exacerbation of disease in lupus-prone models, and shifts 
autoantibody specificities to RNA (63, 64).  Reducing TLR7 gene expression ameliorates 
disease and increases survival (63).  Hence, the combination of self-proteins and TLR 
ligands within immune complexes and on the surface of apoptotic cells can mistakenly 
activate autoreactive B cells and result in autoimmunity. 
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1.3  Arresting and silencing Sm-specific B cells 
Sm-specific autoantibodies are a hallmark of both human and murine lupus.  To 
identify the mechanisms that regulate Sm-specific B cells, the 2-12H Tg mice were 
generated (35, 65).  In this model, an Ig heavy chain, 2-12H, was identified from an Sm-
specific hybridoma derived from an MRL/lpr mouse.  The 2-12H chain pairs with a 
variety of light chains, giving rise to B cells specific for Sm and/or ss-DNA.  B cells from 
the 2-12H model express BCRs of multiple affinities that develop and are regulated on a 
non-autoimmune background.   
Tolerance to Sm is dependent on several cell types.  B cells are the most obvious 
suspects in SLE since disease pathology is mediated by autoantibodies.  In vivo, Sm-
specific B cells are regulated since 2-12H Tg mice have low titers of anti-Sm antibodies 
(35, 66).  However, ex vivo non-subsetted 2-12H B cells (uncontaminated by DCs and 
MΦs) are activated by TLR stimulation (LPS, CpG, dsRNA) in vitro but their Ig 
secretion is lower than that of C57BL/6 controls (35, 67).  The follicular (FO) B cell 
subset is repressed by DCs and MΦs secreting IL-6 and sCD40L, while secretion by the 
MZ B cell subset is partially repressed, but only by MΦs and sCD40L (45).  Some MZ B 
cells and peritoneal B-1 cells ignore endogenous levels of Sm, but an increase in the 
number of apoptotic cells can activate peritoneal and MZ B cells (66, 68, 69).  Sm-
specific B cells arrested at the pre-plasma cell stage, interrupting plasma cell 
differentiation and preventing Ig secretion (32)   
Restricting the light chain that pairs with 2-12H allowed for the analysis of Sm-
specific B cells of moderate and low affinity (32, 70).  The 2-12H/Vκ4 Tg mouse was 
generated to examine regulation of higher affinity anti-Sm responses (70).  B cells from 
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this mouse are distributed among splenic transitional, FO, and MZ subsets, as well as the 
peritoneal B-1 subset (70).  2-12H/Vκ4 B cells are anergic and all subsets are 
hyporesponsive to LPS in vitro.  Additionally, MZ B cells exhibit a block in BCR 
signaling (70).  LPS-stimulated 2-12H/Vκ4 B cells are repressed by IL-6 and sCD40L 
(unpublished data).  To study low-affinity anti-Sm responses, the 2-12H/Vκ8 Tg mouse 
was created (32).  In this model, only transitional and FO B cells are present and these 
cells are regulated by anergy (32).  As in the previous anti-Sm models, 2-12H/Vκ8 B 
cells are susceptible to IL-6- and sCD40L-mediated repression (44, 45).     
T cells are implicated in SLE and Sm-specific T cells are present in the repertoires 
of both normal and autoimmune mice (71).  Sm-specific T cells in 2-12H Tg mice are 
anergic and do not proliferate in response to B cells presenting Sm (71).  Anergic T cells 
are also unable to upregulate CD40L and provide costimulation to their cognate B cells 
(72).  Anti-Sm B cells do not secrete Ig in vivo (35, 65), perhaps because they are 
deprived of T cell costimulation.  However, in autoimmune situations, autoreactive T 
cells induce class-switching and somatic hypermutation of anti-Sm B cells, resulting in 
high levels of pathogenic high-affinity IgG autoantibodies (73, 74).  Paradoxically, anti-
Sm B cells are required to tolerize Sm-specific T cells from C57BL/6 mice, but they 
activate Sm-specific T cells from MRL/lpr mice (71, 75, 76).  This indicates that 
although T cells are necessary for the development of autoantibodies and disease, they 
are also regulated by autoreactive B cells in normal individuals.    
DCs and MΦs regulate innate and adaptive immune responses by tolerizing or 
activating T and B cells.  The continued ingestion and presentation of self-antigens or the 
acute presentation of foreign antigen by DCs/MΦs either tolerizes or activates T cells to 
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drive adaptive immune response.  The activation of DCs during innate immune responses 
induces the secretion of IL-6 that promotes immunity by releasing CD4
+
 T-helper cells 
from their inhibitory functions (77).  This promotes polyclonal activation of naive B 
cells, the production of neutralizing antibody and the clearance of the invading pathogen.  
 In addition to regulating T cells, DCs and MΦs affect the fate of B cells.  They 
activate naïve B cells by secreting type I interferon, IL-6, and B lymphocyte stimulator 
(BLyS) (78-80).  They also repress Ig secretion by B cells that have been chronically 
exposed to antigen.  Our laboratory showed that DCs and MΦs regulate autoantibody 
production, in part through their secretion of IL-6 and sCD40L (44, 45).  Repression is 
selective in that naïve B cells (not chronically exposed to antigen) are unaffected by the 
presence of IL-6 and sCD40L while Ig secretion by autoreactive B cells is repressed 
(Figure 1A).  Coupled with the data showing that IL-6 de-represses regulatory T cells, a 
mechanism emerges explaining how the pleiotropic affects of IL-6 produced by DCs and 
MΦs simultaneously promotes immunity and represses autoimmunity during innate 
immune responses.   
Signal transduction through many cell surface receptors influences neighboring 
receptors.  For example, crosstalk between the IFN-αβ and IL-6 receptor (IL-6R) 
signaling pathways augment transcription factor binding and gene expression in mouse 
embryonic fibroblasts (MEFs) (81).  Similarly, stimulation of B cells with sCD40L, IL-4, 
and LPS reprograms the BCR signaling pathway, enhancing ERK activation and 
bypassing the requirement for phosphatidylinositol 3-kinase (PI3-K) (82-86).  The 
findings that only B cells chronically exposed to self-antigen are susceptible to repression 
by IL-6 and sCD40L suggests that chronic BCR-derived signals “reprogram” the 
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outcome of IL-6R and CD40 signal transduction.  On a molecular level, the ability of IL-
6 and sCD40L to repress Ig secretion reflects diminished BLIMP-1 and XBP-1 mRNA 
and protein levels.  These data indicate that regulation occurs upstream of transcriptional 
activation.  In support of this, pharmacologically inhibiting MEK restores LPS-induced 
Ig secretion.  This suggests that the ability of IL-6/sCD40L to repress TLR4-induced Ig 
secretion is MEK/ERK-dependent (unpublished data).   
Susceptibility of B cells to IL-6/sCD40L requires that B cells be chronically 
exposed to antigen, consistent with a central role for the BCR in tolerance.  High affinity 
neo-self-antigens direct a unique tolerance scheme compared to low-affinity self-
antigens.  Anergic B cells from high affinity models are characterized by elevated 
phospho-ERK (42, 87).  In addition, the binding of high affinity antigen to the BCR and 
constitutive MEK/ERK activation is sufficient to repress TLR4 and TLR9-induced Ig 
secretion (27, 28).  In the low affinity Sm model (2-12H/Vκ8) basal phospho-ERK levels 
are comparable to those in the HEL model.  However, unlike the HEL model, the binding 
of soluble SmD or snRNPs coupled with elevated phospho-ERK levels does not repress 
TLR-induced Ig secretion (unpublished data).  This indicates that ERK is only part of the 
“BCR-derived” signals that regulate innate immune responses in vivo.  Although B cells 
expressing high affinity receptors can be repressed by IL-6 and sCD40L, antigen 
stimulation is sufficient.  In contrast, B cells expressing low affinity receptors for bona 
fide self-antigens (Sm and ssDNA) do not achieve sufficient BCR-derived signals to 
influence TLR4-induced Ig secretion and depend on additional signals from IL-
6/sCD40L (unpublished data).  
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The finding that DCs secrete IL-6 while MΦs secrete IL-6 and sCD40L suggests 
that the anatomical location within the secondary lymphoid organs might dictate how 
autoreactive B cells are regulated.  Marginal zone B cells are solely repressed by sCD40L 
while FO B cells are repressed by IL-6 and sCD40L (45).  This specificity may result 
from the anatomic location, since different subsets of DCs and MΦs localize to specific 
regions of the spleen.  For example, B cells are retained in the marginal zone by MΦs 
(88) and they are regulated by MΦ-derived sCD40L.  However, upon activation and 
differentiation into pre-plasma cells, they may become susceptible to repression by IL-6 
secreted by DCs within the periarteriolar lymphoid sheath (PALS).  Thus, depending on 
the anatomical location of the autoreactive B cell, DCs and/or MΦs can repress 
autoantibody production during innate immune responses.  
 
1.4  Failed tolerance: Sm-specific autoantibodies in a murine model of SLE 
MRL/lpr mice are a well-characterized murine model of SLE, with adult-onset 
disease mediated by autoantibody deposition and tissue destruction.  The prevalence of 
anti-Sm autoantibodies in human SLE patients and MRL/lpr mice is approximately 25% 
(89, 90).  BCR Tg models have been bred onto the MRL background, allowing B cells of 
known specificities to be followed throughout development.  Developmental arrest, 
follicular exclusion, and receptor editing are defective in MRL/lpr mice (91, 92).  
Expression of the 2-12H transgene in MRL/lpr mice increases the prevalence of the anti-
Sm response, accelerates disease, and leads to higher serum anti-Sm levels (65).  Sm-
specific B cells from 2-12H mice are arrested at the pre-plasma cell stage, while B cells 
from the 2-12H/MRL/lpr mice bypass this checkpoint and become activated (93).   
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 The presence of class-switched autoantibodies in MRL/lpr mice suggests a 
breakdown in tolerance within the adaptive immune response.  In MRL/lpr mice where 
somatic hypermutation and isotype switch recombination are blocked (AID
-/-
), lupus-like 
symptoms such as glomerulonephritis, proteinuria, and immune complex deposition are 
ameliorated (94).  Early studies showed a critical role for T cells in disease because 
thymectomized MRL/lpr mice failed to develop lupus-like disease (95).  Subsequently, it 
was shown that defects in central deletion and the number and function of T-regulatory 
cells allow CD4
+
 T-helper cells to activate autoreactive B cells, induce terminal 
differentiation and autoantibody production  (96-101).  
Dysregulation of the innate immune system is apparent in MRL/lpr mice (39).  
Immune complexes containing RNA or chromatin stimulate RF-specific B cells through 
TLR7 and TLR9 to secrete anti-Sm and anti-chromatin (38, 39).  Consistent with a role 
for TLRs, autoantibody responses were reduced in MyD88
-/-
/ MRL/lpr mice (39) and 
disease was ameliorated (102).  TLR7
-/-
/ MRL/lpr mice exhibit reduced autoantibody titer 
and gene duplication of TLR7 shifts autoantibody specificities toward RNA, exacerbating 
disease (63, 64).  This reveals TLR7 as a key receptor in promoting autoimmunity when 
tolerance is overcome (63, 103).  Like TLR7
-/-
 mice, TLR9
-/-
/ MRL/lpr mice exhibited 
lower titers of anti-DNA autoantibodies.  However unlike TLR7
-/-
 mice, they remain 
plagued by accelerated kidney disease and increased mortality (103).  These data suggest 
that TLR9 induces anti-DNA responses but also has an anti-inflammatory effect, possibly 
through its induction of regulatory T cells (104, 105).  The function of regulatory T cells 
in TLR9
-/-
/MRL/lpr mice is impaired, potentially allowing autoreactive cells to 
exacerbate disease (106).  These data indicate that innate immune responses have 
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tremendous and opposing effects on autoantibody production and disease in MRL/lpr 
mice.  
Defects in DC/MΦ-mediated tolerance are evident in lupus-prone mice.  Our 
studies indicate that secretion of IL-6 and sCD40L by DCs/MΦs, as well as 
reprogramming of IL-6R and CD40 in autoreactive B cells, promote tolerance during 
innate immune responses.  This implies that defects in either the secretion of IL-
6/sCD40L or the selective response of autoreactive B cells to these factors regulate 
autoantibody production.  Our studies indicate that DCs and MΦs from MRL/lpr mice 
are unable to repress autoreactive B cells (Figure 1B).  Defects in DC/MΦ-mediated 
repression are coincident with diminished secretion of IL-6 and sCD40L and failure to 
sustain IL-6 mRNA production and activation of the IκB/NFκB pathways (107).  
Similarly, we found that IL-6 and sCD40L fail to repress B cells from lupus-prone mice 
(unpublished data).  The finding that lupus-prone mice harbor defects in DCs/MΦs and B 
cells suggests the influence of an environmental stimulus.  
 
1.5  Apoptotic cells: dangerous in death 
Apoptotic cells pose a unique challenge to the immune system since they are a 
rich source of nuclear antigens, including DNA, immune complexes, nucleosomes, 
histones, snRNPs and snRNAs, Ro, La, and Sm.  These self-antigens can be modified by 
phosphorylation and/or alternate protein cleavage, revealing novel epitopes that were not 
available during the induction of B and T cell tolerance (108-111).  During cell death, 
self-antigens are distributed in large and small blebs on the cell surface and act as targets 
for autoreactive B cells in a membrane-bound, multimeric form (112-114).  The display 
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of self-antigens on apoptotic cells is necessary to develop autoantibodies.  For instance, 
autoantibodies to cytoplasmic but not nuclear antigens develop when nuclear 
fragmentation is blocked in apoptotic cells (115).  Therefore, it is imperative that 
scavenger cells such as MΦs and DCs quickly clear apoptotic cells and their associated 
self-antigens to minimize inflammatory and autoimmune responses.      
Apoptotic cells are bound and cleared by a variety of receptors on DCs and MΦs.  
Ingestion of apoptotic cells reduces the secretion of proinflammatory cytokines by DCs 
and MΦs, inhibiting their maturation and controlling the activation of T cells and 
autoimmune responses to apoptotic cells (116-121).  Decreased clearance of apoptotic 
cells and defects in phagocytosis by MΦs in SLE patients and lupus-prone mice may lead 
to autoimmunity (69, 108, 122-124).  The increase in apoptotic cells and antigens could 
dysregulate DCs and MΦs, triggering a chronic anti-inflammatory response that 
downregulates the production of cytokines important for B cell tolerance (45, 107). 
If apoptotic cells fail to be cleared efficiently, they may become necrotic and 
expel self-antigens and TLR ligands that are opsonized by autoantibodies, forming 
immune complexes (125, 126).  Like apoptotic cells, immune complexes (ICs) present 
self-antigens in a multimeric form and enhance phagocytosis by DCs and MΦs (127, 
128).  While apoptotic cells stimulate anti-inflammatory responses, ICs bind to Fc 
receptors (FcRs) and elicit inflammatory responses from MΦs and DCs (128).  Individual 
FcRs have distinct activating and inhibitory functions to ensure balance in a normal 
immune system.  Activating FcRs include FcγRI and FcγRIII, which phagocytose ICs 
and provoke inflammatory responses from DCs and MΦs (129-131).  These receptors are 
necessary and sufficient for glomerulonephritis in (NZB/NZW) F1 mice (132-134).  Co-
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ligation of TLR9 and FcγRIII by chromatin:IC induces more DC activation than ligation 
of FcγRIII alone, indicating that TLRs synergize with FcR signaling (135).  In contrast to 
the activating FcRs, FcγRIIB is an inhibitory FcR with various functions depending on 
cell type.  It modulates MΦ phagocytosis, DC maturation, BCR signaling, IgG secretion, 
and the expansion of autoreactive IgG-producing B cells (134, 136-145).  Autoantibodies 
and glomerulonephritis develop in certain strains of mice deficient in FcγRIIB, affirming 
its role in preventing autoreactive B cell activation (146, 147).  Additionally, antigen 
internalized by DCs through FcγRIIB, but not FcγRI or FcγRIII, is presented in its native 
form and activates antigen-specific B cells (148).  Immune complexes and FcRs have 
important roles in the immune system, but their dysregulation can result in autoantibody 
secretion and nephritis. 
Clearance of apoptotic cells and their associated autoantigens is crucial in 
preventing activation of B cells, DCs, MΦs, and T cells.  When mice are immunized with 
apoptotic cells or exhibit a defect in apoptotic cell clearance, Sm-specific antibodies are 
detectable in the serum and MZ and B-1 B cells are inappropriately activated (66, 68, 69).  
This suggests that recognition of autoantigens on apoptotic cells can drive B cell terminal 
differentiation (66, 68).  Impaired clearance of apoptotic cells in Fas
lpr
 (69) and mer
kd
 
(149, 150) mice prevents BCR-mediated reprogramming of IL-6R and CD40 
(unpublished data).  These data suggest that exposure of autoreactive B cells to apoptotic 
cells or immune complexes can impact DC/MΦ-mediated tolerance.  In summary, 
apoptotic cells and the self-antigens they display can play both autoimmune and anti-
inflammatory roles.  Imbalances in apoptotic cell clearance or cellular responses result in 
inflammatory responses and autoimmune disease. 
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1.6  Selective repression: new treatments for SLE? 
Systemic lupus erythematosus (SLE) is primarily a B cell-mediated autoimmune 
disease, with symptoms arising from autoantibody deposition and inflammation in target 
organs, such as the kidneys, skin, and brain.  Until recently, treatments for SLE were 
dependent on immunosuppression, which depresses immune function and causes 
dangerous side effects such as opportunistic infections (151).  Therapies that target 
specific cell types or biological processes are now being developed, with the hopes that 
they will be more powerful and have less harmful side effects.  For instance, chimeric 
anti-CD20 (rituximab), depletes peripheral B cells and reduces the severity of SLE 
symptoms in many patients (152).  However, a subset of patients is resistant to rituximab 
treatment (151).  Additionally, rituximab recently failed a late-stage study when its 
efficacy in achieving a clinical response was no greater than a placebo (153).  In murine 
studies of human CD20, B cells in autoimmune-prone strains were refractory to depletion 
by rituximab (154), compared to non-autoimmune-prone strains.  Other biological agents 
being studied or developed target complement activation, B cell-T cell interactions, 
cytokines, TLRs, interferon, or direct removal of antibodies from circulation.  However, 
developing therapies to target each lupus-related autoantigen would be cumbersome and 
slow.  A more efficient approach would be a therapy that selectively targeted autoreactive 
B cells through a common trait to restore tolerance.  In previous studies, we determined 
that DC- and MΦ-mediated repression via IL-6 and sCD40L is effective on B cells of 
multiple specificities.  These data suggest that any B cell chronically exposed to antigen 
would be susceptible to DC/MΦ-mediated tolerance.  We are currently determining 
whether the lack of these soluble factors promotes autoimmunity in normal mice during 
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innate immune responses.  Preliminary data indicate that Sm-specific B cells adoptively 
transferred into chimeric mice lacking IL-6 and sCD40L become activated and secrete 
autoantibodies (unpublished data).  This is consistent with our model indicating that 
DCs/MΦs and their secreted products regulate autoreactive B cells during innate immune 
responses.  Future experiments will examine if tolerance can be restored in lupus-prone 
mice reconstituted with a mix of autoimmune and non-autoimmune hematopoietic stem 
cells.  If DC/MΦ-mediated tolerance is found to be defective in SLE patients, future 
therapies could target their in vivo activation or introduce normal DCs/MΦs to reinstate B 
cell tolerance of newly emerging B cells following B cell depletion therapy.  One 
approach would be nonmyeloablative bone marrow transplant (BMT) or 
nonmyeloablative hematopoietic stem cell transplant (HSCT) to promote mixed 
chimerism.  This may reinstate tolerance by providing a pool of DCs/MΦs that repress 
autoreactive B cells.  Such an approach has shown promise in controlling B cell mediated 
autoimmune disease in humans and mouse models (155-160), resulting in remission of 
rheumatoid arthritis in a human patient (158) and reduction in lupus-like disease in mice 
(155, 157).   
 
1.7  Summary 
 The autoreactive B cells that incite multi-organ damage in SLE patients become 
dysregulated long before clinical symptoms appear.  Autoantigens and TLR ligands 
released from apoptotic cells can overcome the tolerance of autoreactive B cells.  
Autoreactive T cells provide costimulation and promote the secretion of high-affinity, 
class-switched autoantibodies.  These autoantibodies can bind nuclear self-antigens, form 
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immune complexes, and provoke inflammatory responses from DCs and MΦs.  
Fortunately, DCs and MΦs specifically repress autoreactive B cells during TLR 
stimulation by secreting IL-6 and sCD40L.  Restoring normal DC and MΦ function in 
SLE patients might repress autoreactive B cells and re-establish balance among the 
complex components of the immune system. 
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1.9  Figures 
 
Figure 1.1.  DCs and MΦs repress antibody secretion from autoreactive B cells via 
IL-6 and sCD40L.  (A) In non-autoimmune mice, B cell tolerance is maintained during 
innate immune responses by DCs and MΦs.  Although TLR stimulation promotes Ig 
secretion by B cells, it simultaneously induces DCs and MΦs to secrete IL-6 and 
sCD40L.  These soluble factors repress Ig secretion from autoreactive B cells while 
allowing innate stimuli to produce a polyclonal response by naïve B cells.  (B) In lupus-
prone mice, DCs and MΦs are defective in the production of IL-6 and sCD40L, allowing 
both autoreactive and naïve B cells to produce Ig in response to TLR stimulation.  
 
 
 
 
 
 
CHAPTER II 
Tolerogenic ERK signaling prevents differentiation of autoreactive B cells 
during innate immune responses
34 
 
2.1 Abstract 
 Systemic lupus erythematosus (SLE) highlights the dangers of dysregulated B 
cells and the importance of initiating and maintaining tolerance.  In addition to central 
deletion, receptor editing, peripheral deletion, receptor revision, anergy, and indifference, 
we have described a mechanism of B cell tolerance wherein dendritic cells (DCs) and 
macrophages (MΦs) regulate chronically antigen-experienced B cells during innate 
immune responses.  In part, DCs and MΦs repress antigen-experienced B cells by 
releasing interleukin-6 (IL-6) and soluble CD40 ligand (sCD40L).  This mechanism is 
selective in that IL-6 and sCD40L do not affect Ig secretion by naïve cells during innate 
immune responses.  In this manuscript, we show that repression by IL-6 and sCD40L is 
mediated by ERK activation and distinctive subcellular localization.  This elaborate 
mechanism allows differential regulation of naïve and antigen-experienced B cells, 
permitting vigorous immune responses in the absence of autoimmunity   
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2.2  Introduction 
 The innate immune system pioneers the response to pathogens, promoting an 
inflammatory response and activation of a variety of immune cells.  B cell activation and 
immunoglobulin (Ig) secretion are crucial for an effective early response and efficient 
clearance of pathogens.  A broad swath of B cell specificities is critical in combating an 
array of pathogens during both the innate and adaptive immune responses, but the threat 
of autoimmunity is inherent in this diversity.  Breaches in B cell tolerance can result in 
autoimmune diseases such as systemic lupus erythematosus (SLE).  Since innate immune 
responses are inherently non-specific, it seems that these responses must incorporate 
tolerance mechanisms that distinguish between naïve and chronically antigen-
experienced B cells.  We recently identified a tolerance mechanism that selectively 
represses Ig secretion by autoreactive B cells during innate immune responses. We find 
that chronically antigen-experienced B cells are maintained in an unresponsive state by 
dendritic cells and macrophages that secrete IL-6 and/or sCD40L in response to innate 
stimuli binding Toll-like receptors (TLRs).  DC/MΦ-mediated tolerance is reversible in 
vitro; removal of dendritic cells and macrophages allow previously unresponsive B cells 
to secrete Ig in response to TLR ligands.  Treating de-repressed B cells with dendritic 
cells, macrophages, recombinant IL-6 (rIL-6) or recombinant soluble sCD40L (rsCD40L) 
restores the repressed phenotype.  The repressive effect of IL-6 and sCD40L is limited to 
chronically antigen-experienced B cells and naïve B cells remain competent to secrete Ig 
(1-3).  This suggests that chronic B cell receptor (BCR) ligation in vivo affects the 
outcome of IL-6 receptor (IL-6R) and CD40 signal transduction.  In effect, these 
receptors are “reprogrammed.”  In similar situations, IFN-αβ signaling and sCD40L, IL-
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4, and LPS reprogram the IL-6R and the BCR, respectively (4-9).  Our finding that DCs 
and MΦs selectively regulate autoreactive B cells provides a cellular explanation for the 
ability of the immune system to mount polyclonal responses to pathogens without 
promoting a break in tolerance.  
The molecular basis for the selective repression of antigen-experienced B cells 
during innate immune responses remains unclear.  However, others have shown that BCR 
signaling opposes TLR-induced Ig secretion by antigen-experienced B cells and that this 
repression is mediated by ERK activation.  In this report, we show that inhibiting 
extracellular signal-regulated kinase (ERK) activation during rIL-6 or rsCD40L 
stimulation prevents their repression of LPS-induced Ig secretion.  The repression 
mediated by IL-6 and sCD40L is targeted upstream of plasma cell transcription factors 
such as BLIMP-1 and XBP-1.  Analysis of ERK phosphorylation showed that neither IL-
6 nor sCD40L drastically changed the levels of activated ERK.  However, chronically 
antigen-experienced B cells maintained higher basal phosphorylation of ERK.  Finally, 
we determined that the subcellular localization of activated ERK is differentially 
regulated in naïve versus antigen-experienced B cells.  These findings reveal an 
additional layer of antigen-experienced B cell regulation by DCs/MΦs during innate 
immune stimulation.  Identifying the molecular basis of IL-6/sCD40L-mediated 
repression may afford unique opportunities for therapeutics that obviate the need for 
immunosuppression in B cell-mediated autoimmune diseases.   
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2.3  Materials and Methods 
Mice 
2-12H/V Tg and 2-12H Tg mice were created as previously described (10, 11).  2-12H/ 
V mice were created and provided by Stephen Clarke (manuscript in press).  C57BL/6 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  All mice
 
were 8 
to 16 weeks old at the time of analysis.  Animals were
 
maintained in an accredited animal 
facility at University of
 
North Carolina (Chapel Hill, NC). 
 
Reagents  
Recombinant IL-6 (rIL-6) was purchased from BD Biosciences (San Diego, CA) and 
Peprotech (Rocky Hill, NJ).  Recombinant soluble CD40L (rsCD40L) was from R&D 
Systems (Minneapolis, MN).  Fluorochrome- or biotin- labeled antibodies specific for 
CD9, CD19, CD3, CD11b, and CD11c were purchased from BD Biosciences.  
Antibodies specific for phospho-ERK and total ERK1/2 were purchased from Cell 
Signaling Technologies.  Anti-BLIMP-1 was purchased from Novus Biologicals 
(Littleton, CO).  Antibodies specific for XBP-1, lamin A, and beta-tubulin were obtained 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  Horseradish peroxidase-
conjugated secondary antibodies for immunoblotting were purchased from Promega 
(anti-rabbit-HRP, Madison, WI) or Invitrogen (anti-mouse IgG1-HRP, Carlsbad, CA).  
187.1 (anti-κ), HB100 (anti-IgMa), RS3.1 (anti-IgMa), 33-60 (anti-IgM), B7.6 (anti-IgM), 
and 2.4G2 (CD16/32) were
 
purified from hybridoma culture supernatant using Protein G
 
Sepharose (GE Healthcare, Piscataway, NJ)
 
or MEP HyperCel (BioSepra, Marlborough, 
MA) and biotinylated if necessary (Pierce, Rockford, IL).  Sodium orthovanadate was 
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obtained from Millipore (Billerica, MA).  Protease inhibitors (phenylmethanesulfonyl 
fluoride (PMSF), dithiothreitol (DTT), aprotinin, alpha-1-antitrypsin, and leupeptin), and 
LPS from E. coli 055:B5 was purchased from Sigma (St. Louis, MO), and LPS from E. 
coli 0111:B4 was purchased from Invivogen (San Diego, CA).  The MEK1 inhibitor 
U0126 was purchased from Calbiochem (San Diego, CA) and resuspended in dimethyl 
sulfoxide (DMSO, Sigma).   
 
B cell purification 
Splenic B cells were isolated by negative selection (StemCell Technologies, Vancouver, 
Canada).  B cells were 90-95% pure (with fewer than 10% dendritic cells and 
macrophages), as determined by flow cytometry.  Marginal zone (MZ) B cells were 
depleted from C57BL/6 splenocytes by supplementing the EasySep antibody mixture 
with biotinylated anti-CD9.   
   
LPS stimulation 
Purified B cells (1 x 10
5
/per well) were cultured in the presence or absence of Sigma LPS 
(30ug/mL) for four days.  Optimal amounts of rIL-6 (20 ng/mL), rsCD40L (25-75 
ng/mL), and U0126 (0.5 μM) were added at the initiation of the cultures.  Cell-free 
culture supernatants were harvested and IgM
a
/ or total IgM secretion was measured by 
ELISA.    
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ELISA 
IgM
a
/from 2-12H/V8 and2-12H/V4 B cell culture supernatants was captured with 
rat anti-mouse (187.1) and detected with anti-IgMa-biotin (HB100-biotin), and 
streptavidin-alkaline phosphatase (Sigma) as described (11).  Total IgM from C57Bl/6 B 
cell culture supernatants was captured with rat anti-mouse IgM (33-60) and detected with 
rat anti-mouse IgM-biotin (B7.6) and streptavidin-alkaline phosphatase.  IgM
a
 from 2-
12H cell culture supernatants was captured with rat anti-mouse IgM
a
 (RS3.1) and 
detected with anti-IgM
a
-biotin (HB100-biotin) and streptavidin-alkaline phosphatase.    
The standard for all ELISAs consisted of purified mouse IgM
a
/TEPC 183, Sigma).  
Data were plotted as percent of control, which was calculated as the percent secretion 
relative to cultures of LPS-stimulated purified B cells.   
 
Flow cytometry 
Single-cell suspensions of splenocytes were prepared and red blood cells
 
were lysed 
using TAC lysis solution (1 M Tris, 0.15 M ammonium
 
chloride, and 0.1 M EDTA).  All 
staining was done in phosphate-buffered saline with 2% Fetal Clone II (Hyclone, Logan, 
UT).  Fc receptors were blocked with anti-CD16/32 (2.4G2) for 5 min
 
at room 
temperature.  Surface markers were stained for 30 minutes at 4ºC in the dark.  Cells were 
analyzed at the University of North Carolina
 
Flow Cytometry Facility (Chapel Hill, NC) 
using a Cyan flow cytometer
 
(Dako, Carpinteria, CA).  Data were analyzed using Summit 
software (Dako). 
 
All data represent cells that fell within the lymphocyte gate
 
determined 
by forward and side scatter.  One to 5 x
 
10
5
 cells per sample were analyzed. 
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Real-time PCR 
Total RNA was extracted from 1-2 x 10
6
 B cells using TRIZOL (Invitrogen) as 
recommended by the manufacturer.  cDNA was prepared with random hexamers and M-
MLV reverse transcriptase (Invitrogen, Carlsbad, CA) and
 
analyzed in triplicate real-time 
PCR reactions.  For relative quantification of message levels of Xbp-1, and secreted IgM, 
primers were designed using Primer3 (http://frodo.wi.mit.edu) and verified by 
dissociation analysis as well as gel electrophoresis and cloning and sequencing of PCR 
products (Table 2.1).  Primers for Blimp-1 and 18s RNA have been described ((12, 13).  
ABsolute™ QPCR SYBR® Green ROX (500nM) Mix (ABgene, Epsom, UK) was used 
with the following conditions: 2 min at 50ºC, 10 min at 95 °C
 
for initial denaturing, 
followed by 40 cycles of 95 °C for
 
15 s and 62 °C for 1 min, ending with a dissociation 
step of 95ºC for 15 s, 62ºC for 20 s, and 97ºC for 15 s to ensure that single products were 
amplified.  Reactions
 
were performed on an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems, Foster City, CA).
  
Quantification of transcripts relative to 
18s RNA transcripts
 
was determined using the Ct method (14) and expressed as fold-
induction relative to 18s RNA.  
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Table 2.1  Real-time PCR primers and their sequences.   
Primer Sequence 
Blimp-1 forward 5’-TGTTGGATCTTCTCTTGGAAAA-3’ 
Blimp-1 reverse 5’-GTGTAAAGTAGACTGCCTTGA-3’ 
Xbp-1 (total) forward 5’-ACACGCTTGGGAATGGACAC’-3’ 
Xbp-1 (total) reverse 5’-CCATGGGAAGATGTTCTGGG-3’ 
18s forward 5’-TCAAGAACGAAAGTCGGAGGTT-3’ 
18s reverse 5’-GGACATCTAAGGGCATCACAG-3’ 
 
Message levels of IL-6 receptor and GAPDH RNA were measured by real-time PCR 
using ABI On-Demand TaqMan primers and FAM-labeled probes (Applied Biosystems) 
according to the manufacturer’s directions.  Fluorescence was measured in triplicate real-
time reactions by an ABI Prism 7000 SDS thermocycler and relative CT values were 
obtained from ABI Prism 7000 SDS software.  Using the ΔΔCT method, fold-induction 
values of IL-6 receptor were calculated relative to 18s RNA.   
 
Immunoblotting 
Purified splenic B cells were either lysed ex vivo or cultured with LPS alone (30 μg/mL) 
or in combination with rIL-6 (20 ng/mL) or rsCD40L (optimal dose of 25 or 75 ng/mL) 
for three days.  3 x 10
6
 cells were lysed in buffer containing 1% Igepal CA-630 (formerly 
known as NP-40, Sigma) and protease and phosphatase inhibitors 
(phenylmethanesulfonyl fluoride (PMSF), aprotinin, alpha-1-antitrypsin, leupeptin, and 
sodium orthovanadate).  Whole-cell lysates were separated by SDS-PAGE, transferred to 
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PVDF membrane in a semi-dry blotting apparatus, and immunoblotted for phospho-ERK 
and total ERK or BLIMP-1 and XBP-1.  HRP-conjugated antibodies and ECL or ECL+ 
(GE Healthcare) were used to detect proteins.       
 
Nuclear and cytoplasmic extraction 
Purified splenic B cells were stimulated with LPS alone or in combination with rIL-6 or 
rsCD40L for 30 minutes.  15 x 10
6
 cells were disrupted by hypotonic lysis and 
cytoplasmic and nuclear fractions were prepared as described previously (15, 16) with 
modifications.  Protease and phosphatase inhibitors (described above, plus DTT) were 
added to both cytoplasmic and nuclear extract buffers.  Protein concentrations were 
determined by the Bradford method (Bio-Rad) (17).  Cytoplasmic (5μg) and nuclear 
(10μg) extracts were separated by SDS-PAGE and immunoblotted as above with 
phospho-ERK, total ERK, lamin A, and beta-tubulin.   
Statistical analysis 
When comparing antibody secretion
 
in treated and untreated cultures, the one-sample t 
test was used.  The unpaired t test with Welch’s correction was used to test for differences 
in antibody secretion between
 
experimental groups.  Statistical analyses were performed 
with
 
GraphPad Prism (La Jolla, CA).   
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2.4 Results 
IL-6 and sCD40L regulate immunoglobulin secretion by antigen-experienced B cells 
 B cells expressing the 2-12H transgene recognize the self antigen Sm with a range 
of affinities depending on the light chain that is expressed.  2-12H/Vκ8 B cells bind Sm 
with low affinity and fail to respond to LPS stimulation in ex vivo splenic cultures.  These 
anergic B cells comprise an excellent system to study the regulation of B cells specific 
for a bona fide self-antigen.  We previously reported that splenic 2-12H/Vκ8 B cells are 
repressed by IL-6 and sCD40L produced by dendritic cells and macrophages in response 
to LPS (2, 3).  In LPS-stimulated cultures of low-affinity 2-12H/Vκ8 B cells, rIL-6 and 
rsCD40L repressed 47% and 63% of Ig secretion, respectively (Figure 1A).  This 
mechanism of regulation is not limited to low-affinity Sm-specific B cells.  A range of 
BCR affinities for Sm is apparent in 2-12H mice due to their unrestricted light chain (10).  
LPS-induced Ig secretion from 2-12H B cells is repressed 34% by rIL-6 and 54% by 
rsCD40L (Figure 1B).  2-12H/Vκ4 B cells bind Sm with a moderate affinity and are also 
susceptible to rIL-6- and rsCD40L-mediated repression (47% and 35%, respectively, 
Figure 1C).  In contrast, naïve C57BL/6 B cells (Figure 1D) are not significantly 
repressed by these cytokines, indicating that continuous exposure to self-antigen in vivo 
is necessary to “reprogram” the IL-6 receptor and CD40 to repress Ig secretion.  The 
level of IL-6 receptor (CD126) message is not significantly different between antigen-
experienced and naïve B cells (Figure 1E), suggesting that the specificity of this 
repression is determined by a difference in signaling or downstream gene expression.  In 
contrast, CD40 expression is increased on 2-12H/Vκ8 B cells compared to C57BL/6 B 
cells (Figure 1F).  However, it has been observed that CD40 is upregulated by BCR 
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signaling and is increased on other anergic B cells that have presumably encountered 
antigen and are primed for T cell costimulation (18, 19).  Therefore, higher expression of 
CD40 on 2-12H/Vκ8 B cells could be due to antigen experience in vivo and this increase 
in expression, along with receptor reprogramming, could potentially explain the increased 
susceptibility of 2-12H/Vκ8 cells to sCD40L-mediated repression.           
 
IL-6 and sCD40L regulate transcription factors involved in plasma cell differentiation 
 Since IL-6 and sCD40L repress Ig secretion, we examined several transcription 
factors involved in plasma cell differentiation.  BLIMP-1 is often referred to as the 
“master regulator” of plasma cell differentiation and immunoglobulin secretion (20).  
This transcription factor is responsible for extinguishing the mature B cell program by 
repressing Bcl-6, Pax5, and c-myc, while promoting immunoglobulin production and 
secretion through other factors such as XBP-1 (20-22).  Levels of Blimp-1 message 
(Figure 2A) were reduced in 2-12/Vk8 cells treated with rIL-6 (by 49%) or rsCD40L (by 
47%).  We expected that BLIMP-1 protein levels would be similarly repressed.  BLIMP-
1 was induced by LPS but reduced 50% with rIL-6 treatment and 60% with rsCD40L 
treatment.  XBP-1 also plays an important role in Ig secretion, coordinating the unfolded 
protein response (21, 23).  Because XBP-1 is induced by BLIMP-1, we predicted that 
rIL-6 and rsCD40L would repress Xbp-1 message and proteins levels as well.  Message 
levels of Xbp-1 in cultures treated with LPS and IL-6 decreased by 69% (Figure 2A). 
rsCD40L repressed Xbp-1 message levels by 58%.  As expected, XBP-1 protein levels 
reflected the decrease in message levels.  Both rIL-6 and rsCD40L repressed XBP-1 
protein levels by more than 60%.  These results indicate that IL-6 and sCD40L exert their 
   
 
 45 
repressive influence upstream of key transcriptional factors that control Ig secretion by 
chronically antigen-experienced B cells.   
 
IL-6- and sCD40L-mediated repression is rooted in tolerogenic ERK activation 
 Antigen-experienced B cells are subject to chronic, tolerogenic BCR ligation in 
vivo and constant BCR occupancy is required to maintain anergy (24, 25).  Others have 
shown that chronic ERK activation represses LPS- and CpG-induced Ig secretion in hen 
egg lysozyme-specific (HEL-Ig) B cells and that this repression can be reversed by 
pharmacologically inhibiting MEK (26, 27).  Interestingly, both IL-6R and CD40 
signaling induce ERK activation (28-30).  Therefore, we predicted that IL-6- and 
sCD40L-mediated repression might be dependent on ERK activation resulting from IL-
6R or CD40 signaling.  We cultured 2-12H/Vκ8 B cells with LPS, rIL-6 or rsCD40L, and 
the MEK inhibitor, U0126.  When ERK activation was inhibited in 2-12H/Vκ8 B cells by 
U0126 treatment, rIL-6 and rsCD40L were no longer able to repress LPS-induced Ig 
secretion (Figure 3).  These data indicate that rIL-6- and rsCD40L-mediated repression of 
antigen-experienced B cells is dependent on ERK activation.     
 
Basal ERK phosphorylation is increased in anti-Sm B cells 
 Increases in basal ERK phosphorylation have been observed in antigen-
experienced B cells versus their naïve counterparts (31, 32).  This increase has been 
ascribed to chronic ligation of the BCR by self antigen.  However, HEL-specific B cells 
have a very high affinity for HEL.  Low-affinity interactions with self antigens such as 
Sm are more physiologically relevant, but it is not known whether these interactions 
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result in increased basal ERK phosphorylation.  We examined phosphorylation of ERK in 
freshly isolated naïve (C57BL/6) and antigen-experienced (2-12H/Vκ8) B cells and 
observed that 2-12H/Vκ8 B cells had higher basal ERK phosphorylation than C57BL/6 B 
cells (Figure 4).  It is conceivable that in vivo, both high- and low-affinity self antigens 
confer tolerance by chronically ligating the BCR and activating ERK.   
 
Unique subcellular localization of phosphorylated ERK in chronically antigen-
experienced B cells  
 The ERK MAP kinase signaling cascade is quantitatively, temporally, and 
spatially regulated to prevent inappropriate activation or duration of receptor-mediated 
signaling (33).  We have examined the amplitude and temporal patterns of ERK 
activation by rIL-6 and rsCD40L in naïve (C57BL/6) and antigen-experienced (2-
12H/Vκ8) B cells.  rIL-6 and rsCD40L induced equivalent levels of ERK 
phosphorylation in naïve and antigen-experienced B cells within 30 minutes and duration 
of phosphorylation was not consistently longer in either C57BL/6 or 2-12H/Vκ8 B cells 
(data not shown).  Since the magnitude and duration of ERK phosphorylation did not 
appear to vary with chronic antigen experience, we theorized that the subcellular 
localization of phosphorylated ERK may be differentially regulated.  ERK is anchored in 
the cytoplasm by its association with MEK, which contains a nuclear export signal (33).  
When ERK is activated, it generally dissociates from MEK and translocates to the 
nucleus, but certain stimuli can induce phosphorylation without translocation (33).  We 
stimulated naïve and antigen-experienced B cells with LPS alone or in combination with 
rIL-6 or rsCD40L and isolated cytoplasmic and nuclear fractions.  These extracts were 
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immunoblotted for phosphorylated and total ERK as well as cytoplasmic and nuclear 
proteins.  When we compared the distribution of phosphorylated ERK, differences 
between naïve and antigen-experienced B cells were evident.  It was evident that in naïve 
B cells, LPS stimulation caused an increase in phosphorylated ERK in the nucleus 
regardless of rIL-6 and rsCD40L stimulation (Figure 5A).  In contrast, when antigen-
experienced B cells were stimulated with LPS, more phosphorylated ERK was evident in 
the nuclear fraction than in the cells stimulated with LPS combined with either rIL-6 or 
rsCD40L (Figure 5B).  It appears that rIL-6 and rsCD40L alter the localization of 
activated ERK in antigen-experienced B cells compared to naïve B cells.  However, it is 
unclear how phosphorylated ERK is anchored in the cytoplasm during IL-6- and 
sCD40L-mediated repression.   
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2.5 Discussion 
 The innate immune system mounts a vigorous defense against pathogens by 
recognizing and responding to pathogen-associated molecular patterns (PAMPs) such as 
LPS and CpG.  This polyclonal response is swift and robust, but inherently nonspecific.  
This lack of specificity is potentially hazardous because cells specific for autoantigens 
can trigger a bystander autoimmune response.  For instance, there is a strong association 
between EBV seroconversion and SLE (34), and SLE patients have elevated Epstein-Barr 
virus loads in their blood (35).  Additionally, during viral immunization of transgenic 
mice expressing a viral neo-self antigen, autoreactive B cells can evade negative selection 
in the periphery and become memory B cells (36).  These autoreactive B cells can be 
reactivated by a second immunization; perhaps the presence of PAMPSs in subsequent 
infections would be sufficient to reactivate this pool of autoreactive B cells.  A 
mechanism to discriminate between naïve and autoreactive B cells is crucial for a safe, 
effective immune response to pathogens.  Ideally, the same polyclonal activators that 
activate naïve B cells would induce tolerance in autoreactive, antigen-experienced B cells 
to prevent unintentional autoimmunity.  Our studies have shown that IL-6 and sCD40L, 
via ERK activation, repress LPS-induced Ig secretion in chronically antigen-experienced 
transgenic B cells but do not significantly affect naïve B cells.  These soluble factors 
effectively repress B cells from several transgenic mouse models with low or 
intermediate BCR affinity, including 2-12H, 2-12H/Vκ4, 2-12H/Vκ8, as well as high 
affinity B cells from HEL-Ig x sHEL mice (2, 3).  This mechanism specifically targets 
chronically antigen-experienced B cells and therefore would be an extremely valuable 
tool in silencing autoreactive B cells in human diseases such as SLE.   
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 IL-6- and sCD40L-mediated repression of Ig secretion in chronically antigen-
experienced B cells is mediated by ERK and reversible with pharmacological inhibitors 
of MEK.  Basal ERK phosphorylation is increased in chronically antigen-experienced 2-
12/Vκ8 B cells compared to naïve C57BL/6 B cells, similar to antigen-experienced B 
cells from HEL-Ig x sHEL mice (31, 32).  Since LPS, IL-6, and sCD40L all activate 
ERK, we initially predicted that ERK activation would be greater in repressible 2-
12H/Vκ8 cells compared to naïve C57BL/6 B cells.  However, we observed no 
quantitative differences in the magnitude of ERK phosphorylation between antigen-
experienced and naïve B cells.  Additionally, ERK activation was sustained for similar 
periods of time in both antigen-experienced and naïve B cells.  However, the effects of 
activated ERK can be regulated by its subcellular localization (33, 37, 38).  After ERK is 
activated, it translocates to the nucleus where it phosphorylates a variety of transcription 
factors (39, 40).  ERK lacks any obvious nuclear export signals (NES) or nuclear 
localization signals (NLS).  Therefore, it is reliant on MEK to either retain it in the 
cytoplasm or release it to allow nuclear translocation (33, 41, 42).  Other proteins such as 
kinase suppressor of Ras (KSR) can act as scaffolding that binds MEK and ERK and 
facilitates MAPK signaling (43).  We observed reduced nuclear localization of activated 
ERK in repressed antigen-experienced B cells compared to naïve B cells.  Therefore, it 
appears that the subcellular localization, rather than the magnitude and duration of ERK 
activation, may regulate the differential effects of IL-6- and sCD40L-mediated repression 
in naïve and chronically antigen-experienced B cells.   
 Although differential localization of activated ERK is coincident with IL-
6/sCD40L-mediated repression, additional studies are necessary to determine if exclusion 
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of activated ERK from the nucleus is necessary or sufficient for repression of antigen-
experienced B cells.  To determine if the exclusion of activated ERK from the nucleus is 
sufficient for repression, antigen-experienced B cells could be retrovirally transduced 
with a MEK1/ERK2 fusion construct that is constitutively active and localized to the 
cytoplasm and assess if the B cells fail to secrete Ig (44).  We predict expression of this 
construct would constitutively repress Ig secretion because ERK would be maintained in 
the cytoplasm.  To determine if exclusion of activated ERK from the nucleus is necessary 
for repression, a second MEK1/ERK fusion protein could be transduced into antigen-
experienced B cells.  In this construct, the four leucines of the MEK1 NES are mutated to 
alanine, blocking nuclear export (LAMEK1/ERK2) (44).  We predict expression of this 
construct would prevent IL-6/sCD40L-mediated repression of antigen-experienced B 
cells since activated ERK would be constitutively localized in the nucleus.    
 Activated ERK translocates to the nucleus and phosphorylates transcription 
factors such as ETS-1.  ETS-1 negatively regulates BLIMP-1 and can repress plasma cell 
differentiation (45, 46).  Decreased nuclear levels of activated ERK could result in 
decreased ETS-1 phosphorylation and impact its regulation of BLIMP-1 and plasma cell 
differentiation.  Phosphorylation of ETS-1 and other ERK targets could be examined to 
determine the impact of decreased nuclear localization of activated ERK.  These data 
could identify potential links between ERK and transcription factors such as BLIMP-1 
and XBP-1.  This information could provide additional targets for regulating antigen-
experienced B cells during innate immune responses.    
.  The autoreactive B cells that wreak so much damage in SLE patients become 
dysregulated long before any clinical symptoms of disease.  Genetic and environmental 
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factors come together to unbalance all the normal mechanisms of tolerance.  Other than 
immunosuppressive and B cell-depleting therapies, there is currently no way to silence 
these autoreactive cells while preserving the ability to mount a vigorous immune 
response against pathogens.  Treatment options would be vastly improved if a therapy 
could incorporate a selective mechanism of tolerance such as the ERK-mediated 
repression described in this study.   
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2.7 Figures 
 
Figure 2.1.  IL-6 and sCD40L selectively repress Ig secretion by chronically antigen-
experienced B cells.  B cells from 2-12H/Vκ8 (A), 2-12H (B), 2-12H/Vκ4 (C), or 
C57BL/6 (D) mice were stimulated with LPS (30 μg/mL) or LPS combined with 
recombinant IL-6 (rIL-6, 20 ng/mL) or recombinant soluble CD40L (rsCD40L, optimal 
dose of 25 or 75 ng/mL) for four days.  IgM
a/κ (2-12H/Vκ8 and 2-12H/Vκ4), IgMa (2-
12H), or total IgM (C57Bl/6) were quantitated by ELISA.  LPS-stimulated B cells 
(100%) secreted 1.73-18.01 μg/ml Ig (A), 12.93-78.49 μg/ml (B), 7.06-26.75 μg/ml (C), 
and 16.81-27.50 μg/ml (D) from at least three experiments.  (E), Ex vivo B cells were 
isolated from C57BL/6 or 2-12H/Vκ8 mice, total RNA was extracted, reverse-transcribed 
to cDNA, and levels of IL-6 receptor (IL-6R) relative to GAPDH were determined by 
real-time PCR in 3 experiments.  The levels of IL-6R were not significantly different 
between C57BL/6 and 2-12H/Vκ8 B cells.  (F), Splenocytes from C57BL/6 or 2-
12H/Vκ8 mice were stained for expression of CD19 and CD40 and analyzed by flow 
cytometry.  The relative median fluorescence intensity (MFI) of CD40 on CD19+ cells is 
shown.  The MFI of CD40 on 2-12H/Vκ8 B cells was 1.6-fold higher than that of 
C57BL/6 B cells.  Statistical analysis was performed using 1-sample t test by comparing 
treated and untreated cultures (A-D) or C57BL/6 and 2-12H/Vκ8 B cells (E-F). Data 
represent at least 3 experiments. Error bars represent plus or minus standard error (SEM). 
(*** P<0.001, **P<0.01.)   
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Figure 2.2.  IL-6 and sCD40L treatment causes a decrease in levels of transcription 
factors involved in plasma cell differentiation.  (A-B), 2-12H/Vκ8 B cells were 
stimulated for four days with LPS or LPS combined with rIL-6 or rsCD40L.  Total RNA 
was extracted, reverse-transcribed to cDNA, and relative levels of Blimp-1 (A) and XBP-
1 (B) message were measured by real-time PCR in four experiments.  Statistical analysis 
was performed using 1-sample t test by comparing treated and untreated cultures (A-B).  
Error bars represent plus or minus SEM. (**P<0.01, *P<0.05.)  (C-D), 2-12H/Vκ8 B 
cells were cultured for three days with LPS or LPS combined with rIL-6 or rsCD40L.  
Lysates from 3 x 10
6
 cells were separated by SDS-PAGE and immunoblotted for 
BLIMP-1 (C) and XBP-1 (D).  The density of each band was quantitated with ImageJ and 
the fold changes were calculated.  The data shown represent at least 3 experiments.   
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Figure 2.3.  IL-6- and sCD40L-mediated repression is dependent on ERK activation.  
2-12H/Vk8 B cells were stimulated for four days with LPS or LPS combined with rIL-6, 
rsCD40L, or U0126.  IgM
a/κ levels in the culture supernatant were assayed by ELISA.  
LPS-stimulated B cells (100%) secreted 1.35-18.01 μg/ml in at least four experiments.  
Statistical analysis was performed using 1-sample t test by comparing treated and 
untreated cultures or Welch’s unpaired t test for comparisons between treatments. Data 
represent at least 3 experiments. Error bars represent plus or minus SEM. (*** P<0.001, 
*P<0.05.) 
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Figure 2.4.  Chronically antigen-experienced 2-12H/Vκ8 B cells exhibit higher basal 
phosphorylation of ERK than naïve C57BL/6 B cells.  3 x 10
6
 purified ex vivo 
C57BL/6 and 2-12H/Vκ8 B cells were lysed and the proteins were separated on an SDS-
PAGE gel, transferred to PVDF membrane, and immunoblotted with antibodies specific 
for phosphorylated ERK and total ERK1/2.  The density of each band was quantitated 
with ImageJ and the ratio of p-ERK2 to ERK 2 was calculated.  The data shown represent 
at least three experiments.   
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Figure 2.5.  IL-6 and sCD40L alter the subcellular localization of activated ERK in 
chronically antigen-experienced B cells.  15 x 10
6
 purified ex vivo C57BL/6 (A) and 2-
12H/Vκ8 (B) B cells were stimulated with LPS alone or in combination with rIL-6 and 
rsCD40L for 30 minutes.  Cytoplasmic and nuclear fractions were isolated and the 
proteins were separated on an SDS-PAGE gel, transferred to PVDF membrane, and 
immunoblotted with antibodies specific for phosphorylated ERK, total ERK1/2, lamin A, 
and beta tubulin.  The density of each band was quantitated with ImageJ and the ratio of 
p-ERK2 to ERK 2 was calculated.  Phosphorylated ERK in the nuclear fractions of LPS-
stimulated 2-12H/Vκ8 B cells decreased 38% and 62% with rIL-6 or rsCD40L treatment, 
compared with 27% and 0% reduction in the corresponding C57BL/6 samples.  The data 
shown represent one experiment.     
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 Innate immunity is an ancient defense system based upon the simplest principles 
of pattern recognition.  The adaptive immune system mounts highly specific responses to 
clear and destroy pathogenic targets.  The intersection of the innate and adaptive immune 
systems can lead to uncontrolled inflammation and autoimmunity if cross-reactive self-
proteins are recognized by the innate immune system and in turn trigger a powerful 
adaptive immune response.  In addition to tolerance mechanisms based upon antigen 
recognition by the BCR and TCR, we are uncovering mechanisms that govern innate 
activation of naïve and antigen-experienced B cells.   
 The path to B cell activation and Ig secretion is lined with checkpoints to prevent 
inappropriate activation of autoreactive B cells.  From the earliest stages of development, 
B cells are exquisitely sensitive to the affinities of their BCRs for autoantigens.  In the 
bone marrow, central deletion and receptor editing remove autoreactive B cells from the 
repertoire before they exit to the periphery (1, 2).  Additional trials await new B cell 
emigrants as they enter the spleen and are stimulated by a new set of autoantigens.  
Peripheral deletion, receptor revision, and follicular exclusion eliminate another swath of 
B cells with inappropriate specificities (3-5).  Finally, low-affinity autoreactive B cells 
that bypass the previous mechanisms are held in an unresponsive state upon antigen 
ligation.  Without appropriate costimulatory signals and cytokines to accompany antigen 
ligation, these B cells are suspended in an anergic state (6).  Anergic B cells are unable to 
differentiate into plasma cells and secrete Ig, but may be receptive to BCR or TLR 
signals for proliferation or survival (7).  Although these cells remain quiescent in normal 
individuals, the wide array of autoreactive specificities can be dangerous if tolerance is 
breached by a non-specific innate immune response.   
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 Autoreactive B cells risk polyclonal activation during infection and inflammatory 
responses.  TLRs are sensors of pathogens, transducing signals from a variety of bacterial 
and viral ligands, including LPS, methylated CpG DNA, and ssRNA (8, 9).  However, 
endogenous ligands such as non-methylated CpG DNA and ssRNA are present on the 
surface of apoptotic cells and by DCs and MΦs (Carnathan et al, manuscript in 
preparation).  These TLR ligands are often presented in the context of protein complexes 
such as snRNPs or opsonized apoptotic cells.  Thus, rich arrays of autoantigens have the 
potential to co-ligate the BCR, TLRs, and Fc receptors, creating complex signals capable 
of activating autoreactive B cells (10, 11).   
 Receptor cross-talk allows ligands binding one receptor to regulate the response 
of another receptor to its ligand.  In chronically antigen-experienced cells, it appears that 
the BCR, IL-6R, and CD40 form a tangled web of signaling pathways that alter the 
normal outcomes of TLR signaling.  Elevated basal ERK phosphorylation is observed in 
2-12H/Vκ8, Ars/A1, and HEL-Ig x sHEL B cells, (12, 13), suggesting that the specific 
autoantigens are chronically signaling through the BCR.  High-affinity antigens such as 
HEL are sufficient to repress LPS or CpG-induced Ig secretion via ERK activation (14, 
15).  However, the 2-12H/Vκ8 BCR has a low affinity for its specific antigen (Sm), and 
recombinant Sm is not able to repress LPS-induced Ig secretion in these B cells (data not 
shown).  It is unknown whether a higher valency antigen, such as Sm in the context of 
small nuclear ribonucleic particles (snRNPs) or apoptotic cells, would be able to repress 
2-12H/Vκ8 B cells.  Therefore, an additional mechanism is required to maintain tolerance 
in low-affinity B cells during innate immune stimulation.  
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 We have previously described a mechanism to regulate antigen-experienced B 
cells during a polyclonal, innate immune response (16, 17).  DCs and MΦs are activated 
by TLR ligands and secrete IL-6 and sCD40L, preventing polyclonal activation of 
antigen-experienced B cells in the vicinity.  However, naïve B cells are activated by TLR 
ligands and are not susceptible to DC/MΦ-mediated repression.  In contrast, IL-6 and 
sCD40L can promote activation and proliferation in naïve B cells, leading to plasma cell 
differentiation or germinal center formation (18, 19).  DC/MΦ-mediated tolerance 
appears to be a fail-safe mechanism of repressing antigen-experienced B cells during 
polyclonal stimulation.   
  IL-6R or CD40 signaling provides a source of tolerogenic ERK in low-affinity 
autoreactive B cells.  These soluble factors repressIg production in antigen-experienced 
but not naïve B cells (Figure 1).  It is interesting to consider if the differential effects of 
IL-6R and CD40 signaling in chronically antigen-experienced B cells is a consequence of 
the chronic BCR signaling these cells experience in vivo.  We hypothesize that chronic 
BCR signaling reprograms the IL-6R and CD40 to produce “tolerogenic” instead of 
“activating” phosphorylated ERK.  In naïve B cells or in autoreactive B cells that have 
overcome tolerance, such as 2-12H/MRL/lpr, IL-6 and sCD40L fail to repress Ig 
secretion (data not shown).  The inability of IL-6 or sCD40L to repress autoimmune B 
cells may be due to differences in BCR signaling or a defect in crosstalk between the 
BCR and IL-6R and CD40.  In these mice, we would expect that IL-6- and sCD40L-
induced ERK would behave in an activating manner, similar to naïve B cells, rather than 
its tolerogenic actions in chronically antigen-experienced cells.  Similarly, SLE patients 
exhibit elevated levels of IL-6 and sCD40L in their plasma, but these systemic levels are 
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much lower than the amounts of IL-6 and sCD40L we find necessary to repress Ig 
secretion ex vivo  (20, 21).  Increased sCD40L actually correlates with anti-dsDNA titers 
and disease activity (20, 21).  In these patients, increased IL-6 and sCD40L may actually 
enhance Ig secretion from B cells that have already bypassed all tolerance checkpoints.   
 With these data, we link two unlikely repressive factors to a molecular 
mechanism of anergy that is dependent on ERK activation.  Both IL-6R and CD40 are 
capable of activating ERK in addition to other, more well-known signaling pathways (22-
25).  When it was revealed that chronic BCR signaling induced tolerogenic ERK 
activation (14, 15), we predicted that IL-6R and CD40 signaling also resulted in 
tolerizing ERK activation.  We established that IL-6- and sCD40L-mediated repression 
was dependent on ERK activation and only antigen-experienced B cells were susceptible 
to this mechanism.  With this information, we commenced our search for the molecular 
basis of ERK-mediated repression.   
 Plasma cell differentiation and Ig secretion is a complex process involving many 
signaling molecules and transcription factors.  Since we had previously determined that 
IL-6 and sCD40L repressed secreted Ig protein levels in 2-12H/Vκ8 B cells, we 
systematically worked backwards from Ig secretion to transcription factor levels and the 
ERK/MAPK signaling pathway.  We confirmed that IL-6 and sCD40L also repressed 
secreted Ig message levels (unpublished observations) and concluded that the target of 
repression was upstream of Ig transcription.  We examined the message and protein 
levels of two key transcription factors in plasma cell differentiation, BLIMP-1 and XBP-
1.  These transcription factors were significantly repressed by IL-6 and sCD40L, so we 
focused our search on the regulation of ERK itself.  Like antigen-experienced B cells in 
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other models, 2-12H/Vκ8 B cells exhibit higher basal levels of phosphorylated ERK than 
C57BL/6 B cells.  However, we did not find significant differences in the magnitude of 
IL-6/sCD40L-induced ERK activation in antigen-experienced versus naïve B cells.  In 
both antigen-experienced and naïve B cells, IL-6/sCD40L augmented LPS-mediated 
ERK activation.  Similar levels of phosphorylated ERK were observed in both cell types 
when we stimulated with IL-6 or sCD40L alone.  Therefore, we did not observe 
significant differences in ERK activation by IL-6R and CD40 signaling, despite the 
increased expression of CD40 on 2-12H/Vκ8 B cells.  Next we examined the duration of 
IL-6/sCD40L-induced ERK activation in antigen-experienced and naïve B cells and did 
not observe consistent differences between the two cell types.  Therefore, we eliminated 
differences in quantitative and temporal regulation of ERK activation as a mechanism for 
differential susceptibility of 2-12H/Vκ8 and C57BL/6 B cells.  Finally, we investigated 
the subcellular localization of phosphorylated ERK in antigen-experienced and naïve B 
cells stimulated with LPS and IL-6/sCD40L.  Interestingly, we detected a reduction in 
phosphorylated ERK in nuclear fractions of antigen-experienced B cells stimulated with 
IL-6 or sCD40L.  However, total protein levels of ERK1/2 were not visibly decreased.  
These results suggest that phosphorylated ERK is retained in the cytoplasm in repressed 
B cells, preventing its activation of downstream targets in the nucleus.  After confirming 
these results, our next step would be to determine if nuclear exclusion of ERK is 
necessary and sufficient for repression and if IL-6/sCD40L-stimulation of antigen-
experienced B cells reduces phosphorylation of ERK targets in the nucleus.  Changes in 
phosphorylation of targets such as Ets-1 could impact its regulation of other transcription 
factors and repress plasma cell differentiation (26, 27).  Identifying links between ERK 
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and transcription factors such as BLIMP-1 and XBP-1 could further delineate the 
mechanism of IL-6/sCD40L-mediated repression.    
 In summary, DCs and MΦs differentially regulate antigen-experienced and naïve 
B cell activation during innate immune responses by secreting IL-6 and sCD40L.  IL-6 
and sCD40L induce tolerogenic ERK, which is activated but unable to accumulate in the 
nucleus in antigen-experienced B cells.  In contrast, these soluble factors induce 
activating ERK in naïve B cells, which is phosphorylated and accumulates in the nucleus, 
where it can potentially phosphorylate nuclear targets such as Ets-1.  Knowing the 
molecular intricacies of ERK-mediated repression of autoreactive B cells could yield 
additional targets for therapies that selectively repress autoreactive B cells.  New 
therapies could potentially reprogram the IL-6R or CD40, retain activated ERK in the 
cytoplasm, or prevent activation of transcription factors that link ERK signaling and 
BLIMP-1.  Selective, targeted therapies like these would be a vast improvement over 
current options, which are limited to immunosuppression and global B cell depletion.  
Enhancing DC/MΦ-mediated repression and restoring differential responses to IL-
6/sCD40L in autoreactive B cells in SLE patients and could reset the adaptive immune 
system and allow it to function safely and effectively during innate immune responses.   
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